NanoVibronix, Inc. (NAOV)
NASDAQ: NAOV · Real-Time Price · USD
3.770
-0.140 (-3.58%)
At close: Mar 28, 2025, 4:00 PM
3.672
-0.099 (-2.61%)
After-hours: Mar 28, 2025, 7:59 PM EDT
NanoVibronix Employees
As of December 31, 2023, NanoVibronix had 16 total employees, including 10 full-time and 6 part-time employees. The number of employees increased by 2 or 14.29% compared to the previous year.
Employees
16
Change (1Y)
2
Growth (1Y)
14.29%
Revenue / Employee
$205,688
Profits / Employee
-$192,938
Market Cap
2.70M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NAOV News
- 16 days ago - Successful Independent Study of the NanoVibronix UroShield® Device Published in the Australian and New Zealand Continence Journal - Business Wire
- 18 days ago - NanoVibronix Announces Reverse Stock Split - Business Wire
- 6 weeks ago - NanoVibronix, Inc. Announces Acquisition of ENvue Medical Holdings, Corp. - Business Wire
- 2 months ago - NanoVibronix Advances Development of PainShield and UroShield with Completion of NextGen Prototypes - Business Wire
- 2 months ago - NanoVibronix Announces Completion of Pilot Phase of Clinical Study of UroShield® at the University of Michigan - Business Wire
- 3 months ago - NanoVibronix Secures $12 Million Minimum Purchase Commitment for PainShield with Extension of Distribution Agreement - Business Wire
- 4 months ago - NanoVibronix Provides Business Update - Business Wire
- 6 months ago - NanoVibronix Takes Next Step to Partner with Specialist Urology Company to Expand Sales of UroShield in Germany - Business Wire